NineSigma, representing a Japanese pharmaceutical company, seeks novel drug seeds that can be applied to the treatment of intractable and refractory autoimmune diseases. While proposals for a drug candidate compound are preferred, those with novel unique mechanisms, concepts, or ideas are also welcome to participate.
The client, specializing in autoimmune diseases as a priority focus, aims to develop innovative drugs by conducting open innovation activities with various Japanese and overseas research institutes that have developed drug seeds in the mentioned area.
The client seeks proposals for drug seeds applicable to the treatment of intractable and refractory autoimmune diseases, especially systemic lupus erythematosus (SLE), Sjögren's syndrome (SjS), or systemic sclerosis (SSc); however, proposals for drug seeds applicable to other rare diseases originating from autoimmune are also anticipated.
Submissions to this Challenge must be received by Nov 15, 2020.